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Background: To study the prevalence and define deferential risk factors for ‘Resistant’ hypertension (RHT) in a
hypertensive population of South Asian origin.
Methods: A descriptive cross-sectional study was carried out among hypertensive patients attending clinics at the
Cardiology Unit, Colombo from July-October 2009. All the patients with hypertension who provided informed
written consent were recruited to the study (n = 277). A pre-tested interviewer-administered questionnaire was
used for data collection. A binary logistic-regression analysis was performed in all patients with ‘presence of RHT’ as
the dichotomous dependent variable and other independent co-variants.
Results: Mean age was 61 ± 10.3 years and 50.2% were males. The mean of average systolic and diastolic blood
pressures (BP) were 133.04 ± 12.91 mmHg and 81.07 ± 6.41 mmHg respectively. Uncontrolled BP was present in
41.1% (n = 114) of patients, of which RHT was present in 19.1% (n = 53). Uncontrolled BP were due to ‘therapeutic
inertia’ in 27.8% of the study population. Those with diabetes mellitus, obesity (BMI > 27.5 kg/m2) and those who
were older than 55 years were significantly higher in the RHT group than in the non-RHT group. In the binary
logistic regression analysis older age (OR:1.36), longer duration of hypertension (OR:1.76), presence of diabetes
mellitus (OR:1.67) and being obese (OR:1.84) were significantly associated with RHT.
Conclusion: A significant proportion of the hypertensive patients were having uncontrolled hypertension. Nearly
1/5th of the population was suffering from RHT, which was significantly associated with the presence of obesity and
diabetes mellitus. Therapeutic inertia seems to contribute significantly towards the presence of uncontrolled BP.
Keywords: Resistant hypertension, Prevalence, Risk factors, Sri Lanka, South Asia, Developing countryBackground
Hypertension is a common non-communicable disease
that is prevalent worldwide; it leads to numerous dis-
abling complications such as stroke, atherosclerosis,
retinopathy, chronic kidney disease and cardiac failure
[1]. Majority of patients (>90%) with hypertension suf-
fer from essential or primary hypertension, while the
remaining minority have secondary hypertension. Long
term optimization and control of blood pressure is es-
sential to avoid morbidity and mortality in these* Correspondence: priyanga.ranasinghe@gmail.com
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reproduction in any medium, provided the orpatients. However it is not uncommon to see poorly
controlled hypertension and it is estimated that only
1/3 of patients on treatment have their blood pressures
well controlled [2]. Most causes for poor control is
well known, however a considerable percentage falls
into a category known as ‘resistant hypertension’ of
which pathophysiology and risk factors are not fully
understood [3]. Resistant hypertension is defined as
"Suboptimal control of blood pressure despite using
three antihypertensive agents inclusive of a diuretic,
and patients who need 4 or more drugs to control
blood pressure" [3]. Despite having guidelines on man-
agement of resistant hypertension, it has become a
problem to control blood pressure up to recommendedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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physiology and risk factors.
Studies have shown that older age, obesity, excessive
use of alcohol, and high sodium intake are strongly cor-
related with poor control of hypertension [4,5]. Patient
factors such as compliance and knowledge, and health
care system factors like limitation of resources and lack
of reminders of appointments also plays a major role in
poor blood pressure control [6-10]. Managing resistant
hypertension is difficult and involves expensive testing
to look for underlying secondary causes. Furthermore,
patients with uncontrolled blood pressure are more likely
to have target organ damage and have higher cardiovascu-
lar risks than patients with well controlled blood pressure
[11]. Uncontrolled blood pressure affects patients mental,
physical and social well being, while also increasing the
health care expenditure of a country.
Sri Lanka is a middle income developing country in
the South Asian region with a population of over 20
million. In 2005, nearly 1/5th of the population of Sri
Lanka was suffering from hypertension and the preva-
lence is expected to increase further in the coming de-
cades [12]. Furthermore, cardio- and cerebro-vascular
diseases for which hypertension is an important risk
factor, are the leading causes of hospital deaths in Sri
Lanka, and cause specific mortality rates are higher
among Sri Lankans in comparison to affluent countries
[13]. The prevalence rate for hypertension in urban
India is 29-45% in men and 25-38% in women, while
data from other South Asian countries are sparse [14].
Furthermore, studies from developing countries have
shown that hypertension is more common among
South Asian immigrants than among the native white
population [15]. Genetic and environmental risk factors
are important in aetio-pathogenesis of hypertension and
genetic variations could be the reason for these differences
in prevalence. Indeed, approximately a quarter of blood
pressure associated loci reported appear to be common in
people of South Asian ethnicity [16].
There are numerous studies and published guidelines
from developed countries on the prevalence, risk factors
and management of ‘Resistant’ hypertension. However,
presently there are no studies from developing South
Asian countries. The present study aims to study the
prevalence of ‘Resistant’ hypertension in a hypertensive
population of South Asian origin and define deferential
risk factors in the same population.
Methods
This descriptive cross sectional study was conducted
over a period of 3 months from 1st of March 2009 to
30th of May 2009. Ethical approval for the study was
obtained from the Ethics Review Committee, Faculty of
Medicine, University of Colombo, Sri Lanka.Study population and sampling
Patients were recruited from a cohort of hypertensive pa-
tients attending follow-up clinics at the Institute of Cardi-
ology of the National Hospital of Sri Lanka (NHSL).
Situated in Colombo the NHSL is the largest tertiary care
hospital in Sri Lanka. There were about 50 hypertensive
patients visiting daily (excluding Sundays) for follow up to
the cardiology clinic, these patients are given clinic num-
bers on the first come basis and they come to clinics usu-
ally once per month. In order to choose the sample for our
study we used a random sampling technique. In each week
we selected three random days to visit the clinic. On each
day of study we first selected all the patients with hyperten-
sion from the daily clinic register. These patients were then
arranged in ascending order according to their clinic num-
ber. The first patient was chosen randomly from hyperten-
sive patients 1 to 10 and then every third patient thereafter
was invited for the study. Patients who gave the informed
written consent were included in the study. The patients
who visited the clinic for the 1st time, patients who were
too ill/unable to answer the questionnaire and patients
who did not consent were excluded from the study.
Study instrument and data collection
A pre-tested expert-validated interviewer administered
questionnaire was used for data collection (Annexure 1).
The following data were collected; socio-demographic
details, duration of disease, medication history, risk fac-
tors, complications and other co morbidities. The fol-
lowing risk factors were evaluated; history of smoking, alcohol
consumption, drugs (Non-Steroidal Anti-Inflammatory Drugs,
Steroids and Oral Contraceptive Pills), family history, high
salt intake and presence of obesity. The antihypertensive
drugs currently used by the patients were recorded
according to their classes and drugs used for other co-
morbidities were also documented. Patients’ compliance
to treatment was also evaluated.
Height was measured as the maximum distance to the
uppermost position on the head from heels, with the in-
dividual standing barefoot and in full inspiration using
Harpenden stadiometers (Chasmors Ltd, London, UK)
to the nearest 0.1 cm. Body weight was measured using
a SALTER 920 digital weighing scale (SALTER Ltd,
Tonbridge, UK) to the nearest 0.1 kg. Body Mass Index
(BMI) was calculated as weight in kilograms divided by
height squared in meters (kg.m-2). Two consecutive rest-
ing seated blood pressures were recorded 10 minutes
apart, manually using mercury sphygmomanometers.
Patients’ previous 3 blood pressure values were taken
from their medical records in clinic books.
Definitions
Resistant hypertension was defined as “Suboptimal blood
pressure despite using three antihypertensive agents inclusive




Number of patients with
hypertension (%)
p value*
All Resistant Non resistant
(n = 277) (n = 53) (n = 224)
DM 118 (42.6%) 37 (69.9%) 81 (36.1%) < 0.001
IHD 214 (77.3%) 48 (90.6%) 161 (71.9%) < 0.01
Hyperlipideamia 144 (52%) 26 (49.1%) 118 (52.7%) NS
CKD 9 (3.2%) 3 (5.7%) 6 (2.7%) NS
CKD Chronic Kidney Disease, DM Diabetes Mellitus, IHD Ischaemic Heart
Disease, NS Not Significant; *, p values for ‘Resistant’ Vs. ‘Non-resistant’ groups.
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trol blood pressure also called resistant hypertension” [3].
Hypertension treatment targets were < 140/90 mmHg for
patients without any co-morbidities and < 130/90 mmHg
for patients with diabetes mellitus and renal disease [17].
Obesity was defined as BMI ≥ 27.5 kg/m2, based on WHO
criteria for Asians [18]. High salt intake was defined as an
intake of sodium > 3 mg/day based on Food Frequency
Questionnaires. Current cigarette smokers were defined
as adults aged ≥18 years who reported having smoked
≥100 cigarettes during their lifetime and who now smoke
every day or some days [19]. Current alcohol consumption
was defined as ≥ 1 alcoholic drink per month [20]. Pres-
ence of diabetes mellitus, ischaemic heart disease, chronic
kidney disease and hyperlipidaemia were confirmed by
perusal of previous clinic records of the patients.
Data analysis
Data were analyzed using SPSS version 15 statistical
software package (SPSS Inc., Chicago, IL, USA). The sig-
nificance of the differences between means was tested
using z-test. In all analyses a p values < 0.05 was consid-
ered statistically significant. A binary logistic regression
analysis was performed in all patients with ‘presence
of Resistant hypertension (RHT)’ as the dichotomous
dependent variable (0 = RHT absent; 1 = RHT present)
and age, gender (0 = female, 1 = male), duration of
hypertension, current cigarette smoking (0 = no, 1 = yes),
current alcohol consumption (0 = no, 1 = yes), high
salt intake (0 = no, 1 = yes), diabetes mellitus (0 = absent,
1 = present), ischaemic heart disease (0 = absent, 1 =
present), hyperlipidaemia (0 = absent, 1 = present), chronic
kidney disease (0 = absent, 1 = present) and obesity (0 =




Three hundred and ten adults with hypertension were
invited for the study, of which 277 consented to partici-
pate in the study and completed the questionnaires (re-
sponse rate – 86.6%). Mean age was 61 ± 10.3 years
(range 25–83), and 50.2% were males. Majority of the
study population (75.5%) were the age of 55 years. Mean
duration of hypertension was 9.2 years (range 1–38), ma-
jority of the patients were having hypertension for ≤ 9 years
(n = 152/54.9%). The mean of average systolic and dia-
stolic blood pressures of the population was 133.04 ±
12.91 mmHg and 81.07 ± 6.41 mmHg respectively and
73.3% (n = 203) of them were admitted to hospital at
least once due to a complication arising from hyper-
tension (heart failure, cardio-/cerebro-vascular dis-
ease, renal failure, hypertensive emergency, and etc.).
The mean BMI in the study population was 25.02 ±4.52 kg/m2. Majority of the study population (n = 245/
88.4%) had one or more co morbidities and ischemic
heart disease (n = 214/77.3%), hyperlipidaemia (n = 144/
52.0%) and diabetes mellitus (n = 118/42.6%) were the
commonest co-morbidities (Table 1).
Prevalence of resistant hypertension
Either systolic (≥140 mmHg or >130 mmHg in diabetics)
or diastolic (≥90 mmHg or >80 mmHg in diabetics)
blood pressure values measured during two recent clinic
visits one month apart, were high in both visit in 41.1%
(n = 114) of patients. Among these 114 patients, 37
(32.4%) of them were using 3 antihypertensive drugs in-
cluding a diuretic, a proportion of 13.3% when consider-
ing the entire study population. Another 5.7% (n = 16)
of patients who were having normal blood pressures,
were using 4 or more anti-hypertensive drugs. Hence
the percentage of patients with resistant hypertension
according to the definition was 19.1% (n = 53) of the en-
tire study population. The phenomenon of doctors’ failing
to intensify medication regimens at encounters with pa-
tients, who have an uncontrolled risk factor, has been de-
scribed recently as ‘therapeutic inertia’ [21]. Accordingly
the remaining 77 of the 114 patients with uncontrolled
blood pressures were without optimum anti-hypertensive
therapy. Hence, the prevalence of therapeutic inertia in
our study sample is 27.8%.
Anti-hypertensive therapy
All the patients with resistant hypertension were compli-
ant with their therapeutic regime and majority (93.9%)
of the patients in the non-resistant hypertensive
group was also compliant. Table 2 summarizes the
anti-hypertensive drugs and other drugs used in the study
population. Accordingly, the most commonly used drug
in the population was anti-platelets (72.6%). The most
commonly used anti-hypertensive drug was ACE inhibi-
tors (54.5%) followed by β-blockers (51.6%) and Calcium
Channel Blockers (CCBs) (47.3%). In the resistant hyper-
tension group, the most commonly used anti-hypertensive
drug was β-blockers (71.7%) followed by ACE inhibitors
Table 2 Usage of drugs in those with and without resistant
hypertension
Name of drug Number of patients (%) p value*
All Resistant Non
resistant
(n = 277) (n = 53) (n = 224)
Anti-hypertensives
ACEI 151 (54.5%) 37 (69.8%) 114 (50.9%) <0.05
α-blockers 21 (7.6%) 14 (26.4%) 7 (3.1%) <0.001
ARB 94 (33.9%) 22 (41.5%) 72 (32.1%) NS
β-blockers 143 (51.6%) 38 (71.7%) 105 (46.9%) <0.01
CCBs 131 (47.3%) 29 (54.7%) 102 (45.5%) NS
Furosemide 59 (21.3%) 26 (49.1%) 33 (14.7%) <0.001
Spiranolactone 8 (2.9%) 6 (11.3%) 2 (0.9%) <0.01
Thiazide 34 (12.3%) 16 (30.2%) 18 (8.0%) <0.001
Other drugs
Anti platelets 201 (72.6%) 37 (69.8%) 174 (77.7%) NS
Lipid lowering drugs 152 (54.9%) 25 (47.1%) 127 (56.7%) NS
Nitrates 139 (50.2%) 26 (49.1%) 113 (50.4%) NS
ACEI Antgiotensin Converting Enzyme Inhibitors, ARB Angiotensin-II Receptor
Blockers, CCB Calcium Channel Blockers, NS Not Significant; *, p values for ‘Resistant’
Vs. ‘Non-resistant’ groups.
Table 3 Cardiovascular risk factors in those with and
without resistant hypertension
Risk factors Number of patients (%) *p value
All Resistant Non
resistant
(n = 277) (n = 53) (n = 224)
Non modifiable
Age (> 55 years) 202 (72.9%) 46 (86.8%) 156 (69.6%) < 0.05
Gender – Male 139 (50.2%) 28 (52.8%) 111 (49.5%) NS
Gender – Female 138 (49.8%) 25 (47.2%) 113 (50.4%) NS
Family history 126 (45.5%) 29 (54.7%) 97 (43.3%) NS
Modifiable
High salt intake 61 (22.0%) 12 (22.6%) 49 (21.9%) NS
Tobacco smoking 16 (5.8%) 1 (1.9%) 15 (6.7%) NS
Hyperlipidaemia 142 (51.3%) 24 (45.3%) 118 (52.7%) NS
Diabetes mellitus 111 (40.1%) 30 (56.6%) 81 (36.2%) < 0.01
Obesity
(BMI > 27.5 kg/m2)
185 (66.8%) 42 (79.2%) 143 (63.8%) < 0.05
Alcohol consumption 29 (10.5%) 7 (13.2%) 22 (9.8%) NS
BMI Body Mass Index, NS Not Significant; *, p values for ‘Resistant’ Vs.
‘Non-resistant’ groups.
Table 4 Binary logistic regression analysis of factors
associated with resistant hypertension
Risk factor β-coefficient (95% CI) p value
Age 1.36 (1.14 – 1.56) <0.05
Gender – female Reference
male 1.52 (0.67 – 3.47) NS
Duration of hypertension 1.76 (1.26 – 2.28) <0.05
Current smoking - non-smoker Reference
smoker 1.51 (0.25 – 9.01) NS
Alcohol consumption - no Reference
yes 2.81 (0.96 – 8.20) NS
Diabetes Mellitus – absent Reference
present 1.67 (1.31 – 1.97) <0.05
IHD – absent Reference
present 0.59 (0.12 – 2.50) NS
CKD - absent Reference
present 0.79 (0.39 – 1.58) NS
Hyperlipidaemia - absent Reference
present 1.16 (0.54 – 2.48) NS
Obesity - BMI <27.5 Reference
BMI > =27.5 1.84 (1.04 – 3.26) <0.05
High salt intake – absent Reference
present 1.96 (0.94 – 2.95) NS
BMI Body Mass Index, CKD Choric Kidney Disease, IHD Ischaemic Heart Disease.
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α-blockers, β-blockers, furosemide, spiranolactone and
thiazide diuretics were significantly more in the resistant
hypertension group than in the non-resistant hypertension
group (Table 2).
Risk factors
There were no significant difference observed between the
resistant hypertension and non-resistant hypertension
groups for the following modifiable and non-modifiable
cardio-vascular risk factors; gender, family history, high
salt intake, tobacco smoking, alcohol consumption and
hyperlipidaemia (Table 3). Those with diabetes mellitus,
obesity (BMI > 27.5 kg/m2) and those who were older
than 55 years were significantly higher in the resistant
hypertension group than in the non-resistant hypertension
group (Table 3). In the binary logistic regression analysis
older age (OR: 1.36, 95%CI 1.14–1.56), longer duration of
hypertension (OR: 1.76, 95% CI 1.26– 2.28), presence of
diabetes mellitus (OR: 1.67, 95% CI 1.31–1.97) and being
obese (OR: 1.84, 95% CI 1.04–3.26) were significantly as-
sociated with resistant hypertension (Table 4).
Discussion
This is the first report evaluating the control of blood
pressure from Sri Lanka, a developing country in the
South Asian region. Our results demonstrate that blood
pressure control rates are suboptimal in 41.1% of the
local hypertensive population, similar to reports from
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hypertension control includes two different entities; un-
controlled/poorly controlled hypertension and resistant
hypertension. Uncontrolled hypertension is lack of blood
pressure control secondary to poor adherence and/or an
inadequate therapeutic regimen, while treatment resist-
ance is suboptimal blood pressure despite using optimal
therapy. Many studies have suggested the prevalence of
uncontrolled hypertension to be around 50% of patients
being treated for hypertension [25,26]. In the present
study, deficiencies in the quality of hypertension man-
agement were observed despite the fact that patients
were assessed frequently and had satisfactory compli-
ance. The proportion of poorly controlled hypertensive
patients with sub optimal drug management was 27.8%.
It is the physicians’ failure to increase the intensity of treat-
ment among patients with uncontrolled hypertension, a
phenomenon known as therapeutic inertia. Distinguishing
therapeutic inertia from other causes for uncontrolled
hypertension is an important initial step to identify strat-
egies to improve care offered to these patients.
Majority of patients in both resistant (79.2%) and non-
resistant (63.8%) hypertension groups were obese. Obes-
ity is recognized as the sixth most important risk factor
contributing to the overall burden of disease worldwide
[27]. It is said that compared with year 2000, the number
of adults with hypertension is predicted to increase by
60% to a total of 1.56 billion by year 2025 [28]. Further-
more, more than 1 billion adults and 10% of children are
now classified as either overweight or obese [27]. Studies
have shown that the cardiovascular risks in those with
obesity are not significantly increased unless hyperten-
sion is present [29]. This observation emphasizes the
role of hypertension as a mediator through which obes-
ity may cause cardiovascular disease. Our results also
demonstrate that obesity was a significant factor associ-
ated with resistant hypertension in the logistic regression
analysis. Obesity is associated with more severe hyper-
tension, a need for an increased number of medications
and a decreased likelihood of achieving blood pressure
control [30]. The impact of body weight change on the
prognosis in these patients is potentially of relevance when
planning future treatment strategies for uncontrolled
hypertension and its cardiovascular consequences.
This epidemic of obesity and obesity-related hyperten-
sion is paralleled by an alarming increase in the inci-
dence of diabetes mellitus and chronic kidney disease.
We observed a statistically significant relationship be-
tween diabetes mellitus and resistant hypertension in the
logistic regression analysis. Hypertension in diabetics in-
terferes with the rate of development and progression of
diabetic complications, which in turn aggravates the
hypertensive disease. It appears to be universally ac-
cepted that the tight treatment regimes for hypertensionin diabetics reduces cardiovascular risk and slows the
rate of progression of diabetic complications such as dia-
betic nephropathy. Hypertension is usually linked with
renal disease and it is both a cause and a complication
of hypertension. However in our study sample the num-
ber of hypertensive’s with renal disease were minimal,
probably due to the fact that there are specialized clinic
for patients with renal disease at the NHSL, while we
conducted the study in a specialized cardiology clinic.
Furthermore, blood pressure, plasma glucose, and lipids
are continuous variables that exert a dose-dependent
effect on cardiovascular risk [31]. Hence it would be of
interest to see the results of the present analysis
conducted considering these parameters as continuous
variables rather than discreet variables in the future.
Resistant hypertension represents a different phenotype
to the general population and it is reasonable to assume
that genetic factors play a greater role in pathogenesis. In
one of the few genetic evaluations of patients with resist-
ant hypertension, investigators in Finland found that 2β
ENaC and γENaC gene variants were significantly more
prevalent in the patients with resistant hypertension than
in the normotensive controls [32]. A particular allele of
the CYP3A5 enzyme that plays an important role in the
metabolism of cortisol and corticosterone has been associ-
ated in African-American patients with higher systolic
blood pressure levels in normotensive participants and
hypertension more resistant to treatment [33,34]. Indu-
cible nitric oxide synthase (iNOS) is another important
enzyme regulating blood pressure, studies have shown that
the g.2087G > A polymorphism in the iNOS gene affects
the susceptibility to hypertension. Moreover, the S-C-A
haplotype is also associated with responsiveness to antihy-
pertensive therapy [35]. The calcium/calmodulin-dependent
kinase IV (CaMKIV) seems to be involved in blood pressure
regulation mediated via the control of endothelial nitric
oxide synthase activity [36]. In addition the Angiotensinogen
AGT 235 Tallele has also been shown to be an independent
risk factor for resistant hypertension [37]. The heptahelical
G-protein-coupled receptors (GPCRs) represent one of the
largest classes of cell-surface receptors, a wide variety of
GPCRs are involved in blood pressure control. In addition
several intermediaries involved in the GPCR desensitization
process, like the G-protein-coupled receptor kinases (GRKs)
are important in the regulation of vascular tone [38].
Of the seven mammalian GRKs, GRK2 seems to be the
most relevant isoform at the cardiovascular level [38].
Identification of genetic influences on resistance to
current therapies might also lead to development of
new therapeutic targets. However it is important to
understand that a single genetic variant may not reveal
significant associations with resistant hypertension be-
cause their effects may be dependent on gene-gene or
gene-environment interactions.
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for the treatment of hypertension. Among them diuretics
play major role in blood pressure control. However most
of the patients (63.5%) in our study sample were not on
any diuretic, including furosemide, spiranolactone and
thiazide diuretics. It has been said that combinations of
the thiazide-type and potassium-sparing subclasses may
be highly effective, providing nearly optimal therapy for
some, and might be considered more often in the treat-
ment of hypertension [39]. Treatment of hypertension
using a diuretic-based strategy has been effective in
preventing stroke and cardiac disease, a consistent finding
from the earliest randomized clinical trials (1960s) to
present-day large multi-centered studies such as ALLHAT
[40]. Thirteen randomized controlled trials have shown
that first-line β-blockers for elevated blood pressure were
not as good at decreasing mortality and morbidity as other
classes of drugs such as thiazides, CCBs and ACE inhibi-
tors [41]. In our study sample β-blockers were the second
commonly used anti-hypertensive and there were 9 pa-
tients on sole β-blockers therapy of which 4 had uncon-
trolled blood pressure. ACE inhibitors are some of the
most commonly prescribed medications for hypertension.
ACE inhibitors are seen as more appropriate for first-line
use when other high-risk conditions are present, such as
diabetes. It is clear that it is an important role in the treat-
ment of hypertension. In our study sample ACE inhibitors
were the most commonly used anti-hypertensive drug.
There were 13 patients on sole ACE inhibitor therapy, out
of which 6 were having diabetes mellitus and 7 had un-
controlled blood pressure.
There are several limitations that need to be kept in
mind when drawing conclusions from the present study.
The cross-sectional design of our study limits the infer-
ence of causality for the risk factors identified. Therefore,
it is important to conduct prospective studies on resistant
hypertension and look for causality. There was also in-
complete documentation on drug-prescribing decisions
and regarding the hospital admissions due to disease com-
plications. It may have led to an underestimation of the
control of disease and medication intensifications. In
addition, lack of diagnostic laboratory tests may have led
to under ascertainment of co-morbidities. Further-
more, it is said that the mental stress is important as
an aetiological agent for resistant hypertension. How-
ever we did not evaluate the patients stress levels in
the present study. In addition although risk factors such as
Diabetes, Ischaemic Heart Disease and Chronic Kidney Dis-
ease were considered their severity was not evaluated [42].
Conclusions
A significant proportion of the hypertensive patients
were identified as having uncontrolled hypertension.
Nearly one fifth of the population was suffering fromRHT, which was significantly associated with the pres-
ence of obesity and diabetes mellitus. Therapeutic inertia
seems to contribute significantly towards the presence of
uncontrolled blood pressure and its role and causative
factors needs further evaluation.
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